{"id":2261,"date":"2023-06-25T17:55:01","date_gmt":"2023-06-25T17:55:01","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/trimipramine\/"},"modified":"2023-06-25T18:05:20","modified_gmt":"2023-06-25T18:05:20","slug":"trimipramine","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/trimipramine\/","title":{"rendered":"Trimipramine"},"content":{"rendered":"

<\/p>\n

CLINICAL USE<\/h3>\n

Tricyclic antidepressant<\/p>\n

DOSE IN NORMAL RENAL FUNCTION<\/h3>\n

50\u2013300 mg daily in divided doses Elderly: 10\u201325 mg 3 times daily; half the dose should be sufficient for maintenance<\/p>\n

PHARMACOKINETICS<\/h3>\n
  • Molecular weight                           : 410.5 (as maleate)<\/li>\n
  • %Protein binding                           : 95<\/li>\n
  • %Excreted unchanged in urine     : 0<\/li>\n
  • Volume of distribution (L\/kg)       : 31<\/li>\n
  • half-life \u2013 normal\/ESRD (hrs)      : 23\/\u2013
    \n

    DOSE IN RENAL IMPAIRMENT<\/h3>\n

    GFR (mL\/MIN)<\/h4>\n<\/li>\n
  • 20 to 50     : Dose as in normal renal function<\/li>\n
  • 10 to 20     : Dose as in normal renal function<\/li>\n
  • <10           : Dose as in normal renal function
    \n

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES<\/h3>\n<\/li>\n
  • CAPD                : Not dialysed. Dose as in normal renal function<\/li>\n
  • HD                     : Not dialysed. Dose as in normal renal function<\/li>\n
  • HDF\/high flux   : Unknown dialysability. Dose as in normal renal function<\/li>\n
  • CAV\/VVHD      : Unknown dialysability. Dose as in normal renal function
    \n

    IMPORTANT DRUG INTERACTIONS<\/h3>\n

    Potentially hazardous interactions with other drugs<\/li>\n

  • Alcohol: increased sedative effect<\/li>\n
  • Analgesics: increased risk of CNS toxicity with tramadol; possibly increased risk of side effects with nefopam; possibly increased sedative effects with opioids<\/li>\n
  • Anti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone \u2013 avoid concomitant use; increased risk of ventricular arrhythmias with drugs that prolong the QT interval; increased risk of arrhythmias with propafenone<\/li>\n
  • Antibacterials: increased risk of ventricular arrhythmias with moxifloxacin \u2013 avoid concomitant use; concentration reduced by rifampicin<\/li>\n
  • Anticoagulants: may alter anticoagulant effect of coumarins<\/li>\n
  • Antidepressants: enhanced CNS excitation and hypertension with MAOIs and moclobemide \u2013 avoid concomitant use; concentration possibly increased with SSRIs<\/li>\n
  • Anti-epileptics: convulsive threshold lowered; concentration reduced by carbamazepine, primidone, barbiturates and possibly phenytoin<\/li>\n
  • Antimalarials: avoid concomitant use with artemether\/lumefantrine<\/li>\n
  • Antipsychotics: increased risk of ventricular arrhythmias especially with pimozide; increased antimuscarinic effects with clozapine and phenothiazines; concentration increased by antipsychotics<\/li>\n
  • Antivirals: increased tricyclic side effects with amprenavir; concentration possibly increased with ritonavir<\/li>\n
  • Atomoxetine: increased risk of ventricular arrhythmias and possibly convulsions<\/li>\n
  • Beta-blockers: increased risk of ventricular arrhythmias with sotalol<\/li>\n
  • Clonidine: tricyclics antagonise hypotensive effect; increased risk of hypertension on clonidine withdrawal<\/li>\n
  • Dopaminergics: avoid use with entacapone; CNS toxicity reported with selegiline and rasagiline<\/li>\n
  • Pentamidine: increased risk of ventricular arrhythmias<\/li>\n
  • Sibutramine: increased risk of CNS toxicity \u2013 avoid concomitant use<\/li>\n
  • Sympathomimetics: increased risk of hypertension and arrhythmias with adrenaline and noradrenaline; metabolism possibly inhibited by methylphenidate
    \n

    ADMINISTRATION<\/h3>\n

    Reconstition<\/h4>\n

    \u2013<\/p>\n

    Route<\/h4>\n

    Oral<\/p>\n

    Rate of Administration<\/h4>\n

    \u2013<\/p>\n

    Comments<\/h4>\n

    \u2013 .<\/li>\n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Tricyclic antidepressant DOSE IN NORMAL RENAL FUNCTION 50\u2013300<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-2261","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/2261","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=2261"}],"version-history":[{"count":1,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/2261\/revisions"}],"predecessor-version":[{"id":2333,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/2261\/revisions\/2333"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=2261"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=2261"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=2261"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}